Approvals· May 28, 2026 · 7 min read
Topic
BPDCN
Blastic plasmacytoid dendritic cell neoplasm, ultra-rare blood cancer access, CD123-targeted therapy, antibody-drug conjugate coverage, and rare-disease payer policy.
Blastic plasmacytoid dendritic cell neoplasm, ultra-rare blood cancer access, CD123-targeted therapy, antibody-drug conjugate coverage, and rare-disease payer policy.